InterCure has strategically acquired ISHI, gaining access to premium U.S. cannabis technology and brands as the U.S. market anticipates significant regulatory changes.

Target Company Overview

InterCure Ltd. (Nasdaq: INCR) (TASE: INCR), a leading medical cannabis company, has announced the strategic acquisition of ISHI (formerly Botanico Ltd.). This acquisition enhances InterCure's portfolio by granting immediate access to advanced cultivation technologies and established partnerships with renowned U.S. cannabis operators. ISHI is recognized for its premium cannabis brands and innovative technology solutions, making it a valuable asset in the evolving cannabis market.

ISHI prides itself on its exclusive partnership with a top-tier indoor cultivation facility, utilizing sophisticated, AI-driven cultivation optimization systems, and automated production processes. The company has cultivated exclusive alliances with prestigious U.S. cannabis brands, such as The Flowery, which is known for its vertically integrated operations and comprehensive delivery system in Florida. This acquisition aligns with InterCure's strategy to remain competitive in a rapidly changing industry landscape.

Industry Overview

The U.S. cannabis industry is on the verge of significant transformation, bolstered by a potential regulatory shift as the Trump administration considers rescheduling cannabis from Sch